Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin in Panzyga provides a broad spectrum of IgG antibodies that bind to bacteria, viruses and toxins. After infusion, these antibodies circulate in the bloodstream, neutralising pathogens, promoting opsonisation and activating complement, which together restore humoral immunity in individuals with antibody deficiencies.

The dosing regimen for Panzyga is individualized. A prescribing clinician determines the dose based on the patient’s weight, severity of immunodeficiency, and clinical response, and then adjusts the infusion rate and frequency according to therapeutic goals and tolerability.

Human immunoglobulin products are generally considered low risk during pregnancy and lactation because they are derived from pooled plasma and do not contain live agents. However, clinicians should evaluate the risk‑benefit profile for each patient and follow local regulatory guidance.

To order Panzyga, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Panzyga is a 10% liquid IVIG formulation approved in the EU, offering a high concentration of IgG with a low stabiliser profile. Compared with some older IVIG products, it may allow for shorter infusion times and has a comparable safety and efficacy profile, though individual product selection depends on clinician preference and patient tolerance.

Panzyga should be stored at 2‑8 °C (refrigerated) in its original container, protected from light. It must not be frozen or shaken, and any vial that has been kept outside the recommended temperature range should be discarded.

Panzyga is given by intravenous infusion. The product is diluted according to the manufacturer’s instructions and infused over a period that may range from 1 to 4 hours, depending on the patient’s tolerance and the prescribed dose. Infusion rates are adjusted to minimise adverse reactions.

Serious risks include anaphylactic reactions, acute hemolytic transfusion reactions, thromboembolic events, renal impairment and severe hypotension. Patients should be monitored closely during and after infusion, and any signs of these reactions require immediate medical intervention.

Panzyga is contraindicated in individuals with a known severe hypersensitivity to immunoglobulin products or any of its excipients, and in patients with uncontrolled hyperviscosity syndrome. Caution is also advised for those with severe renal insufficiency or a history of thrombotic events.